lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Measles Vaccination in the Presence of Maternal Measles Antibody Reduces All-Cause Child Mortality - A Planned Cohort Study Nested in a Randomised Trial

31 Pages Posted: 7 Apr 2021

See all articles by Christine Stabell Benn

Christine Stabell Benn

University of Southern Denmark - Odense Patient Data Explorative Network (OPEN); Bandim Health Project, INDEPTH Network

Sebastian Nielsen

University of Southern Denmark - Odense Patient Data Explorative Network (OPEN)

Ane Fisker

Bandim Health Project, INDEPTH Network

Sofie Biering-Sørensen

Bandim Health Project, INDEPTH Network

Stine Byberg

Bandim Health Project, INDEPTH Network

Kristoffer J. Jensen

Bandim Health Project, INDEPTH Network

Morten Bjerregaard-Andersen

Bandim Health Project, INDEPTH Network

Amabelia Rodrigues

Bandim Health Project, INDEPTH Network

Cesario Martins

Bandim Health Project, INDEPTH Network

Hilton Whittle

London School of Hygiene & Tropical Medicine

Gaby Smits

National Institute of Public Health and the Environment

Fiona van der Klis

National Institute of Public Health and the Environment; National Institute for Public Health and the Environment (RIVM)

Peter Aaby

Bandim Health Project, INDEPTH Network; Bandim Health Institute - OPEN, Institute of Clinical Research

More...

Abstract

Background:  Several smaller studies suggested that measles vaccination (MV) in the presence of maternal measles antibody (MatAb) reduces all-cause mortality. We tested the hypothesis that children receiving early MV at 4 months in the presence of MatAb would have 35% lower mortality than children receiving MV at 4 months with no detectable MatAb. We further hypothesised that among children, who did not receive early MV, there would be no difference in mortality between those with and without MatAb.

Methods:  The study was an observational study nested within a randomised controlled trial (RCT) of early MV, carried out in Guinea-Bissau from 2011-2019. The RCT compared the mortality between 4 and 60 months of age for children randomised 2:1 to two doses of MV at 4 and 9 months of age or to only one dose of MV at 9 months of age. At enrolment in the RCT, a blood sample was collected from all children. A multiplex immunoassay was used to determine the measles MatAb level; as control exposures, levels of varicella, mumps and rubella antibody were assessed. We assessed overall mortality as a function of randomisation group and presence of MatAb in Cox proportional hazards models.

Results:  6,598 children were enrolled in the RCT, 6,239 (95%) had a valid enrolment blood sample. In children receiving early MV at enrolment, mortality was 50% (95% CI: 20-68%) lower for those vaccinated in the presence of MatAb (n=3132; 51 died) compared with those vaccinated in the presence of no MatAb (n=1028, 31 died). There was no beneficial effect of having MatAb in children who did not receive early MV (test of interaction, p=0.045). The result was specific for measles antibody; no effect was found for varicella, mumps or rubella antibodies. In a meta-analysis of five available studies, MV in the presence of MatAb was consistently associated with lower mortality compared with MV in the absence of MatAb, the combined meta-estimate indicating 55% (35-68%) lower mortality.

Interpretation:  The results support the previous findings that MV in the presence of maternal antibody enhances the beneficial effects of MV on child survival. Earlier measles vaccination should be considered. Further research is needed to examine whether it is beneficial to vaccinate women of fertile age to transfer higher level of maternal antibodies to their children.

Trial Registration (for the RCT): NCT01486355

Funding:   The RCT was funded by an ERC Starting Grant to Christine S Benn (ERC-2009-StG-243149) and by a “Center of Excellence” grant from the Danish National Research Foundation (DNRF108). The work on non-specific effects of vaccines has been supported by the Danish Council for Development Research, Ministry of Foreign Affairs, Denmark [grant number 104.Dan.8.f.], Novo Nordisk Foundation and European Union FP7 support for OPTIMUNISE (grant: Health-F3-2011-261375). The funding agencies had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report.

Declaration of Interests: Authors declare no competing interests.

Ethics Approval Statement: The protocol was approved by the National Ethical Committee in Guinea-Bissau and given consultative approval by the Danish Central Ethical Committee

Suggested Citation

Benn, Christine Stabell and Nielsen, Sebastian and Fisker, Ane and Biering-Sørensen, Sofie and Byberg, Stine and Jensen, Kristoffer J. and Bjerregaard-Andersen, Morten and Rodrigues, Amabelia and Martins, Cesario and Whittle, Hilton and Smits, Gaby and Klis, Fiona van der and Aaby, Peter, Measles Vaccination in the Presence of Maternal Measles Antibody Reduces All-Cause Child Mortality - A Planned Cohort Study Nested in a Randomised Trial. Available at SSRN: https://ssrn.com/abstract=3809819 or http://dx.doi.org/10.2139/ssrn.3809819

Christine Stabell Benn (Contact Author)

University of Southern Denmark - Odense Patient Data Explorative Network (OPEN) ( email )

J. B. Winsløws Vej 4
Odense
Denmark

Bandim Health Project, INDEPTH Network ( email )

Bissau
Guinea-Bissau

Sebastian Nielsen

University of Southern Denmark - Odense Patient Data Explorative Network (OPEN) ( email )

Denmark

Ane Fisker

Bandim Health Project, INDEPTH Network

Sofie Biering-Sørensen

Bandim Health Project, INDEPTH Network

Denmark

Stine Byberg

Bandim Health Project, INDEPTH Network

Kristoffer J. Jensen

Bandim Health Project, INDEPTH Network

Denmark

Morten Bjerregaard-Andersen

Bandim Health Project, INDEPTH Network

Denmark

Amabelia Rodrigues

Bandim Health Project, INDEPTH Network

Cesario Martins

Bandim Health Project, INDEPTH Network

Hilton Whittle

London School of Hygiene & Tropical Medicine

Gaby Smits

National Institute of Public Health and the Environment ( email )

Fiona van der Klis

National Institute of Public Health and the Environment ( email )

National Institute for Public Health and the Environment (RIVM) ( email )

Peter Aaby

Bandim Health Project, INDEPTH Network ( email )

Bissau
Guinea-Bissau

Bandim Health Institute - OPEN, Institute of Clinical Research ( email )

Odense
Denmark